Evidence map›Paper›PMID 41469388›Full record

ArticleCell death discovery2025

UCHL1 stabilizes Twist1 via K11/K63-linked deubiquitination to drive tumor metastasis in non-small cell lung cancer.

Qin Feng, Qianfang Hu, Qinghe Huang, Jingxing Yang, Ying Zhu, Feng Wang, Jianyu Xu, Sha Hu, Rujuan Zheng, Hui Shi and 3 more

Abstract read
In one paragraph

Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qin Feng *Department of Pharmacy, Children's Hospital of Soochow University, Suzhou, China.
Qianfang Hu *Department of Pharmacy, Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China.
Qinghe Huang *Department of Pharmacy, Children's Hospital of Soochow University, Suzhou, China.
Jingxing YangNational Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China.
Ying ZhuDepartment of Pharmacy, Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China.
Feng WangDepartment of Pharmacy, Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China.
Jianyu XuDepartment of Pharmacy, Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China.
Sha HuDepartment of Pharmacy, Children's Hospital of Soochow University, Suzhou, China.
Rujuan ZhengDepartment of Pharmacy, Children's Hospital of Soochow University, Suzhou, China.
Hui ShiDepartment of Pharmacy, Children's Hospital of Soochow University, Suzhou, China.
Zengyan ZhuDepartment of Pharmacy, Children's Hospital of Soochow University, Suzhou, China. zhuzengyan7676@suda.edu.cn.ORCID http://orcid.org/0000-0001-5170-2545
Xinyuan DingDepartment of Pharmacy, Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China. aladdine@163.com.
Wenjuan WangDepartment of Pharmacy, Children's Hospital of Soochow University, Suzhou, China. wangwenjuan1110@163.com.ORCID http://orcid.org/0000-0003-3863-9937

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82172840
6 · The paper itself

Abstract

Deubiquitinating enzymes (DUBs) are critical regulators of protein turnover and have emerged as key players in cancer progression. In this study, we demonstrated that ubiquitin C-terminal hydrolase L1 (UCHL1) is upregulated in non-small cell lung cancer (NSCLC) and drives tumor metastatic progression, and we identified Twist1, a transcription factor that governs epithelial-mesenchymal transition (EMT), as a downstream target of UCHL1. Depletion of UCHL1 attenuated Twist1-mediated metastatic capacity in NSCLC cells both in vitro and in vivo. Mechanistically, UCHL1 directly interacts with Twist1 and stabilizes Twist1 protein levels through the enzymatic cleavage of K11- and K63-linked ubiquitin chains. Clinically, immunohistochemistry of human NSCLC tissues revealed a positive correlation between UCHL1/Twist1 expression and metastatic progression, with elevated levels of both proteins predicting poor prognosis. Our findings reveal a critical pathway through which UCHL1-mediated deubiquitination sustains Twist1 stability, revealing a novel posttranslational regulatory axis involved in cancer metastasis and progression and highlighting promising therapeutic targets for metastatic NSCLC.

Identifiers

PMID41469388
PMCPMC12847959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.